The Irish Times view on PrEP and HIV: A matter of urgency

There should be no delay in proceeding with this vital preventive health initiative

The  drug Truvada, which is used as a pill (pre-exposure prophylaxis – PrEP) to help prevent the contraction of HIV.

The drug Truvada, which is used as a pill (pre-exposure prophylaxis – PrEP) to help prevent the contraction of HIV.

 

The number of people diagnosed with Human Immunodeficiency Virus (HIV) rose by eight per cent last year. There were 531 HIV diagnoses in 2018, up from 492 the previous year. Statistics from the Health Protection Surveillance Centre show the number of people in Ireland diagnosed with HIV has continued to rise in recent years; this contrasts with the EU and European Economic Area where there has been a 20 per cent drop in the rate of new diagnoses among men who have sex with men since 2015.

The increase of HIV rates here is a multifaceted problem that requires diverse solutions. From a preventive health perspective, the HIV prevention drug PrEP (pre-exposure prophylaxis) is safe and highly effective for people at substantial risk of contracting the virus. In this context, the Health Information and Quality Authority’s recommendation to the Government that introducing a PrEP programme here would be cost effective, is an important one.

The Hiqa report estimates that 173 HIV infections could be averted over the course of the first five years of a programme, at a cost of €5.4 million. This cost includes providing the PrEP drug as part of a holistic service that offers frequent monitoring for adherence and side effects, testing for HIV, and advice on safer sex practices.

PrEP is considered cost saving compared with standard care by Hiqa

PrEP is the most recent development in the field of HIV prevention, involving the use of oral antiretroviral therapy in HIV negative people to prevent infection. The Hiqa report estimates that more than 1,700 people would join a PrEP programme in its first year.

With the success of combined anti retroviral therapy in turning HIV infection from a fatal illness to a chronic, manageable condition, the focus has moved from treatment to prevention. When used every day, in combination with condoms, PrEP reduces the risk of HIV infection by up to 99 per cent. With PrEP considered cost saving compared with standard care by Hiqa and pending a short period of public consultation, there should be no delay in proceeding with this vital preventive health initiative.

The Irish Times Logo
Commenting on The Irish Times has changed. To comment you must now be an Irish Times subscriber.
SUBSCRIBE
GO BACK
Error Image
The account details entered are not currently associated with an Irish Times subscription. Please subscribe to sign in to comment.
Comment Sign In

Forgot password?
The Irish Times Logo
Thank you
You should receive instructions for resetting your password. When you have reset your password, you can Sign In.
The Irish Times Logo
Please choose a screen name. This name will appear beside any comments you post. Your screen name should follow the standards set out in our community standards.
Screen Name Selection

Hello

Please choose a screen name. This name will appear beside any comments you post. Your screen name should follow the standards set out in our community standards.

The Irish Times Logo
Commenting on The Irish Times has changed. To comment you must now be an Irish Times subscriber.
SUBSCRIBE
Forgot Password
Please enter your email address so we can send you a link to reset your password.

Sign In

Your Comments
We reserve the right to remove any content at any time from this Community, including without limitation if it violates the Community Standards. We ask that you report content that you in good faith believe violates the above rules by clicking the Flag link next to the offending comment or by filling out this form. New comments are only accepted for 3 days from the date of publication.